调脂药物应用于高脂血症并脂肪肝治疗的临床观察

The clinical efficacy of lipid-lowering drug in hyperlipidemia with fatty liver:one clinical observation

目的 通过常规护肝治疗和联用护肝调脂药物治疗对比了解调脂药物对高脂血症并脂肪肝的临床疗效及安全性影响。方法 将 82例高脂血症并脂肪肝肝功能异常患者随机分为A、B两组。两组用药前TC、TG、HDL C、LDL C、ALT、AST无统计学差异。A组 38例 ,运用能量合剂与甘利欣静点治疗 4周 ,B组 44例 ,运用上述治疗联合地奥脂必妥胶囊口服治疗 4周。结果 A组TC、TG、LDL c及ALT、AST降低不明显 ,HDL c无明显变化 (P >0 .0 5 ) ;B组TC、TG、LDL c及ALT、AST有显著性降低 ,并提高了血脂HDL c水平 (P <0 .0 5 ) ;经过 4周治疗后 ,B组患者TC、TG、ALT、AST明显下降到目标水平 ,与A组比较疗效有显著性差异 (P <0 .0 1) ;用药前后两组查血糖、血尿素氮、血肌酐均无统计学差异。结论 对高脂血症并脂肪肝肝功能异常患者 ,联用地奥脂必妥和护肝治疗疗效好。可明显降低TC、TG、LDL c ,升高HDL c ,并促进ALT、AST好转 ,且不会导致肾功能和血糖代谢异常。

Objective To investigate the clinical efficacy and safety of Chinese lipid-lowering drug Zhibituo combined with hepatic protection drugs on patients of hyperlipidemia with fatty liver.Methods 82 patients were randomly assigned to control group(group A) and treatment group(group B).There were no significant difference between two groups on total cholesterol,triglyceride, LDL-c,HDL-c, and liver function before treatment.38 patients in group A received the baseline treatment with energy mixture and diammonium glycyrrhiznate while 44 patients in group B received Zhibituo combined with the baseline treatment, both groups were treated for four weeks.Results On the measurement of total cholesterol,triglyceride, LDL-c,HDL-c,liver function,there were no significant changes in group A after treatment(P>0.05) while in group B,they were greatly reduced except that HDL-C was enhanced(P<0.05).There was a significant difference on efficacy between the two group(P<0.01).No changes on blood glucose and BUN,plasma creatine were found. Conclusion Treatment with lipid-lowering drug Zhibituo resulted in the decrease of lipid level and improvement of hepatic function on hyperlipidemia with fatty liver patients.No side effects on glucose metabolism and renal function were observed.